Site Search

1. 31.
   AMP/assets/File/advocacy/AMP Future Pandemic White Paper Response.pdf?pass=95

   However, of those reporting this barrier, approximately 60% were academic medical center ... compared to only 30% of commercial reference laboratories ... limitation across laboratories, with 60% of survey respondents reporting that ... chain limitation with 53% of laboratories reporting they ... See for examples of barriers: https://www.genomeweb.com/pcr/coronavirus

   https://www.amp.org/AMP/assets/File/advocacy/AMP Future Pandemic White Paper Res...
2. 32.
   Microsoft Word - Pediatric_SoftTissue

   Tumor of Bone H3-3A (H3F3A) p.G35W (p.G34W), ... Angiomatoid Fibrous Histiocytoma EWSR1::CREB1 (90%), EWSR1::ATF1 fusion diagnosis FISH, NGS ... Sarcoma SMARCB1 (INI1; >95%), SMARCA4 (BRG1) loss (usually deletion ... NUT Carcinoma BRD4::NUTM1 (80%), BRD3::NUTM1 (15%) fusion diagnosis IHC (NUT), FISH ... Renal) SMARCB1 (INI1; >95%), SMARCA4 (BRG1) loss (usually deletion

   https://www.amp.org/AMP/assets/File/education/MIMP/Pediatric_SoftTissue.pdf?pass...
3. 33.
   AMP/assets/AMP_Letter_to_Sec_Becerra_HHS-Statement_LDPs-FINAL-5-10-2021.pdf?pass=4

   1 https://www.hhs.gov/coronavirus/testing/index.html 2 https://www.amp.org/AMP/assets/File/pressreleases ... Press_Release_082120.pdf?pass=4 3 https://www.amp.org/AMP/assets/AACC-ACMG-AMP-Joint%20letter%20of%20support%20for%20HHS%20statement%20on%20LDPs-FINAL.PDF?pass=84 ASSOCIATION FOR ... obtaining an EUA still remain. 4 https://www.amp.org/AMP/assets/File/

   https://www.amp.org/AMP/assets/AMP_Letter_to_Sec_Becerra_HHS-Statement_LDPs-FINA...
4. 34.
   AMP/assets/File/education/MIMP/InheritedConditions.pdf?pass=88

   Detects more than 99% of affected individuals. If positive, additional ... Paternal Deletion (15q11.2-q13) in 65-75% of cases (recurrence risk 1%) • Maternal UPD: 20-30% (recurrence risk 1%) • Imprinting defect 5% (recurrence risk up to 50 %) • Chromosomal rearrangement: 1% (recurrence risk up to 25%) • An imprinting disorder characterized by severe

   https://www.amp.org/AMP/assets/File/education/MIMP/InheritedConditions.pdf?pass=...
5. 35.
   AMP/assets/File/advocacy/Sign_on_letter_comment_extensionLDT_rulemaking.pdf?pass...

   The new regulatory regime also led 1 https://www.360dx. ... europe#:~:text=With%20the%20increase%20in%20resources,tests%20for%20rare%20disease%20patients. 2 https://www.medtechdive.com ... ivdr/616392/3 https://www.medicept.com ... National Hospital 4 https://www.360dx.com ... text=With%20the%20increase%20in%20resources,tests%20for%20rare%20disease%20patients. Children

   https://www.amp.org/AMP/assets/File/advocacy/Sign_on_letter_comment_extensionLDT...
6. 36.
   AMP/assets/File/position-statements/2016/AMP-CAPCommentLetter_BiomarkersOverview...

   For CYP2C19 ultrarapid metabolizers (eg, *17/*17), physicians should consider increasing the dose by 150% (https://www.pharmgkb.org/guideline/ ... reduce the dose by 50% for patients with CYP2C19 poor ... poor metabolizers and a 25% dose reduction for CYP2D6 intermediate ... should be reduced by 50% in patients who are poor ... relief for 98-99% of patients. At the

   https://www.amp.org/AMP/assets/File/position-statements/2016/AMP-CAPCommentLette...
7. 37.
   COST AND VALUE OF GENOMIC SEQUENCING PROCEDURES

   Lives10 millionRepresentativeplan sizeLungcancer incidence.07%Calculatedbased on total ... diagnoses atstage IIB/IV88.2%Wisnivesky et al. Chest ... targeted therapyClinical trialHospice care6%83%4%7%Based on a number ... All Rights Reserved. 6%83%4%7%Standard of CareTargeted TherapyNon ... TherapyClinical TrialHospice Care30%6%37%27%Genomic Sequencing ProceduresTargeted

   https://www.amp.org/AMP/assets/File/advocacy/AMPNGSCostandValueProjectOverviewFe...
8. 38.
   AMP/assets/File/advocacy/AMP_Response_to_PGx_Citizen_Petition_5-4-2020.pdf?pass=47

   Professional Qualifications 1 https://www.regulations.gov/contentStreamer? ... CFR 493.1291 (e) 3 https://www.cdc.gov/mmwr ... elss/ShowProperty?nodePath=/UCMCON/Contribution%20Folders/DctmContent/education/OnlineCourseContent/2017 ... this emerging field, 5 https://www.amp.org/PGxBestPracticesStatement ... molecular pathology professionals 6 https://www.fda.gov/news

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Response_to_PGx_Citizen_Petitio...
9. 39.
   AMP/assets/File/advocacy/AMP_Response_to_PGx_Citizen_Petition_5-4-2020.pdf?pass=71

   Professional Qualifications 1 https://www.regulations.gov/contentStreamer? ... CFR 493.1291 (e) 3 https://www.cdc.gov/mmwr ... elss/ShowProperty?nodePath=/UCMCON/Contribution%20Folders/DctmContent/education/OnlineCourseContent/2017 ... this emerging field, 5 https://www.amp.org/PGxBestPracticesStatement ... molecular pathology professionals 6 https://www.fda.gov/news

   https://www.amp.org/AMP/assets/File/advocacy/AMP_Response_to_PGx_Citizen_Petitio...
10. 40.
    AMP/assets/File/clinical-practice/COVID/AMP_RC_VariantTestingforSARSCOV2_4_28_21...

    February 2021 mutations appeared in around 25% of all the COVID ... offer variant testing. References 1. https://www.cdc.gov/coronavirus/2019 ... Control and Prevention, 2021. 2. https://asm.org/Articles/2019/November ... Society of Microbiology, 2021. 3. https://www.cdc.gov/coronavirus/2019 ... et al. Preprint at bioRxiv https://doi.org/10.1101/2021.03.31.437925 (2021

    https://www.amp.org/AMP/assets/File/clinical-practice/COVID/AMP_RC_VariantTestin...